Clinical Trials Browser

Terminated × dinutuximab × Clear all

NCT02641782 2022-11-04

NB2013-HR

Phase 2 Terminated

Neuroblastoma

NCT02693171 2019-08-05

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

13 enrolled 9 charts

Neuroblastoma